BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC

The approval was supported by the TRIDENT-1 trial studying Augtyro in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.

May 15, 2024 - 04:00

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC

The approval was supported by the TRIDENT-1 trial studying Augtyro in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.

Read the original article

Tags:

Previous Article

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

More efficient bioethanol production might be possible using persimmon tannin to...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

AbbVie wins UK NICE endorsement for subcutaneous Tepkin...

Feb 2, 2024

In counties with more Black doctors, Black people live longer, ‘astonishing’ study finds

In counties with more Black doctors, Black people live ...

Apr 15, 2023

STAT+: Pharmalittle: We’re reading about Wegovy shipments, the NIH director’s plans, and more

STAT+: Pharmalittle: We’re reading about Wegovy shipmen...

Jan 16, 2024